Table 23Results of head-to-head efficacy trials of atypical antipsychotics in patients with behavioral and psychological symptoms of dementia

Study, Year (quality)Medications compared (mean daily dose)NDurationMain efficacy results
Deberdt 2005 (fair)Olanzapine (5.2 mg)
Risperidone (1.0 mg)
49410 weeksNo difference between groups on any measure
Ellingrod 2002 (poor)Olanzapine
Risperidone
198 weeksNo difference between groups on any measure
Fontaine 2003 (poor)Olanzapine (6.65 mg)
Risperidone (1.47 mg)
392 weeksNo difference between groups on any measure
Gareri 2004 (poor)Olanzapine (5 to 10 mg)
Risperidone (1 to 2 mg)
Promazine (50 to 100 mg)
Mean doses not reported
608 weeksA compared with B compared with C Complete regression of symptoms on NPI: 16/20 (80%) compared with 14/20 (70%) compared with 13/20 (70%) (P value not reported)
Mulsant 2004 (poor)Olanzapine (5.22 mg)
Risperidone (0.76 mg)
866 weeksNo difference between groups on NPI; both groups improved from baseline
Rainier 2007 (fair)Quetiapine IR (77 mg)
Risperidone (0.9 mg)
728 weeksNo difference between groups on any measure

Abbreviations: IR, immediate release.

From: Results

Cover of Drug Class Review: Atypical Antipsychotic Drugs
Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].
McDonagh M, Peterson K, Carson S, et al.
Portland (OR): Oregon Health & Science University; 2010 Jul.
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.